Updates from ASRS: nAMD, DR/DME, and RVO Treatment

Updates from ASRS: nAMD, DR/DME, and RVO Treatment is organized by Healio, Vindico Medical Education.

This enduring material is approved for 1 year from the date of original release, August 15, 2025, to August 14, 2026.

Description:
Real-world and long-term outcomes from Pinnacle clinical studies evaluating the management of retinal diseases with second-generation anti-vascular endothelial growth factor (VEGF) therapies continue to evolve. Analysis of these trials provide insights and guidance for the optimal management of patients with neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Staying up-to-date with the latest clinical and real-world outcomes can be challenging, but it is imperative in order to ensure effective integration of second-generation anti-VEGF therapies into clinical practice and support best patient outcomes. In this CE activity, experts in the field review and discuss the latest clinical and real-world studies evaluating the utilization of second-generation anti-VEGF therapies in the management of patients with retinal diseases.

Learning Objectives:
Upon successful completion of this activity, participants should be better able to analyze the latest clinical trial and real-world data to inform treatment decisions for patients with nAMD, DR/DME, or RVO.